Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
复制标题
DOI：
10.1016/j.drugalcdep.2021.108917
复制
发表时间：
2021-10-01
影响因子：
4.2
通讯作者：
Kim TW
中科院分区：
文献类型：
--
作者：
Tsui JI;Leroux BG;Radick AC;Schramm ZA;Blalock K;Labelle C;Heerema M;Klein JW;Merrill JO;Saxon AJ;Samet JH;Kim TW
We conducted a pilot study to assess feasibility of using video directly-observed therapy (DOT) for patients initiating buprenorphine to evaluate whether it is associated with better opioid use disorder (OUD) outcomes when compared to treatment-as-usual (TAU). Pilot randomized controlled trial of adult patients with OUD initiating buprenorphine treatment (n=78) at two sites (Seattle, WA and Boston, MA) from January 2019 to May 2020. Intervention was video DOT using a HIPAA-compliant smartphone application to record taking daily buprenorphine. Study smartphones, text reminders to upload a video, and calendar summaries of video DOT adherence were provided. Main outcomes were 1) percentage of 12 weekly urine drug tests (UDT) negative for illicit opioids and 2) engagement in treatment at week 12 (i.e., having an active prescription for buprenorphine within the last 7 days). Of 78 enrolled, 20 (26%) were female; 29 (37%) non-white; and 31 (40%) homeless. The mean (standard deviation) number of doses confirmed by video was 31% (34%). In intention-to-treat analysis, the average percentage of weekly opioid negative UDT was 50% (95% CI: 40–63%) in the intervention arm versus 64% (95% CI: 55–74%) among controls; RR=0.78 (95% CI: 0.60–1.02, p=0.07). Engagement at week 12 was 69% (95% CI: 56–86%) v. 82% (95% CI: 71–95%) in the intervention vs. TAU arms, respectively; RR=0.84 (95% CI: 0.65–1.10, p=0.20). The video DOT intervention did not result in improvements in illicit opioid use and treatment engagement compared to TAU. The study was limited by low rates of intervention use. ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.
登录
查看更多内容
DOI：
10.15585/mmwr.mm6650a5
发表时间：
2017-12-22
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Olano-Soler H;Thomas D;Joglar O;Rios K;Torres-Rodríguez M;Duran-Guzman G;Chorba T
通讯作者：
Chorba T
影响因子：
4.2
作者：
Cicero, Theodore J.;Ellis, Matthew S.;Kurtz, Steven P.
通讯作者：
Kurtz, Steven P.
影响因子：
158.5
作者：
Fiellin, David A.;Pantalon, Michael V.;Schottenfeld, Richard S.
通讯作者：
Schottenfeld, Richard S.
影响因子：
1.5
作者：
Noe, Shelly R.;Keller, Teresa
通讯作者：
Keller, Teresa
影响因子：
5.5
作者：
Hoffman, Jeffrey A.;Cunningham, Janice R.;Hunt-Glassman, Jonathan
通讯作者：
Hunt-Glassman, Jonathan